Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma

References

• KaravasilisVSeddonBMAshleySAl-MuderisOFisherCJudsonISignificant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcomaCancer200811271585159118278813
   PubMed Web of Science ®Google Scholar
• JudsonIVerweijJGelderblomHDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialLancet Oncol201415441542324618336
   PubMed Web of Science ®Google Scholar
• RyanCWMerimskyOAgulnikMPICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcomaJ Clin Oncol20163438983905
   PubMed Web of Science ®Google Scholar
• TapWDPapaiZVan TimeBARandomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with locally advanced, unresectable or metastatic soft tissue sarcomaAnn Oncol201627483492
   Web of Science ®Google Scholar
• SeddonBStraussSJWhelanJLeahyMWollPJGemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomasThe Lancet Oncology201718101397141028882536
   PubMed Web of Science ®Google Scholar
• CarvalhoIMilaneziFMartinsAReisRMSchmittFOverexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progressionBreast Cancer Res20057R788R79516168125
   PubMed Web of Science ®Google Scholar
• RamosAHDuttAMermelCAmplification of chromosomal segment 4ql2 in non-small cell lung cancerCancer Biol Ther20098212042205019755855
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature20084551061106818772890
   PubMed Web of Science ®Google Scholar
• DolloffNGShulbySSNelsonAVBone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptorOncogene200524456848685416007172
   PubMed Web of Science ®Google Scholar
• AdamsSFHicksonJAHuttoJYMontagAGLengyelEYamadaSDPDGFR-alpha as a potential therapeutic target in uterine sarcomasGynecol Oncol2007104352452817049587
   PubMed Web of Science ®Google Scholar
• ShahGDLoizosNYoussoufianHSchwartzJDRowinskyEKRationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alphaCancer20101161018102620127943
   PubMed Web of Science ®Google Scholar
• LiCWangYLuSMiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor αMol Med Rep20151257072707826324236
   PubMed Web of Science ®Google Scholar
• ZhangZRenXLuXGZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivoCancer Lett2016375117217826940138
   PubMed Web of Science ®Google Scholar
• LiuK-WHuBChengS-YPlatelet-derived growth factor receptor alpha in glioma: a bad seedChin J Cancer20113059060221880180
   PubMedGoogle Scholar
• SkobeMFusenigNETumorigenic conversion of immortal human keratinocytes through stromal cell activationProc Natl Acad Sci U S A1998953105010559448283
   PubMed Web of Science ®Google Scholar
• CaoYMultifarious functions of PDGFs and PDGFRs in tumor growth and metastasisTrends Mol Med20131946047323773831
   PubMed Web of Science ®Google Scholar
• LoizosNXuYHuberJTargeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic targetMol Cancer Ther20054336937915767546
   PubMed Web of Science ®Google Scholar
• JaysonGCParkerGJMullamithaSBlockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volumeJ Clin Oncol200523597398115466784
   PubMed Web of Science ®Google Scholar
• DoiTMaYDontabhaktuniANippgenCNippgenJOhtsuAPhase I study of olaratumab in Japanese patients with advanced solid tumorsCancer Sci2014105786286924816152
   PubMed Web of Science ®Google Scholar
• GerberDEGuptaPDellingerMTStromal platelet-derived growth factor receptor a (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenograftsMol Cancer Ther201211112473248222933705
   PubMed Web of Science ®Google Scholar
• RussellMRLiuQFatatisATargeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasisClin Cancer Res201016205002501020813817
   PubMed Web of Science ®Google Scholar
• ChioreanEGSweeneyCYoussoufianHA phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumorsCancer Chemother Pharmacol201473359560424452395
   PubMed Web of Science ®Google Scholar
• TapWDJonesRLVan TineBAOlaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase lb and randomised phase 2 trialLancet20163881004348849727291997
   PubMed Web of Science ®Google Scholar
• JonesRLUtility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityExpert Rev Cardiovasc Ther200861311131719018683
   PubMedGoogle Scholar
• EbosJMLKerbelRSAntiangiogenic therapy: impact on invasion, disease progression, and metastasisNat Rev Clin Oncol20118421022121364524
   PubMed Web of Science ®Google Scholar
• SchöffskiPChawlaSMakiRGEribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialLancet2016387100281629163726874885
   PubMed Web of Science ®Google Scholar
• ShirleyMOlaratumab: first global approvalDrugs201777110711227995580
   PubMed Web of Science ®Google Scholar
• GerberDECampbellTCSwansonPA randomized phase 2 study of a human antiplatelet-derived growth factor a (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol20143215 suppl80508050
   Web of Science ®Google Scholar
• CassierPAFumagalliERutkowskiPEuropean Organisation for Research and Treatment of CancerOutcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor eraClin Cancer Res2012184458446422718859
   PubMed Web of Science ®Google Scholar
• WagnerAJKindlerHGelderblomHA phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumorsAnn Oncol201728354154628426120
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMJonesRLEfficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trialJ Clin Oncol201634878679326371143
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPEORTC Soft Tissue and Bone Sarcoma Group, PALETTE Study GroupPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet20123791879188622595799
   PubMed Web of Science ®Google Scholar